Advertisement

Cannabinoids pp 657-690 | Cite as

Pharmacokinetics and Metabolism of the Plant Cannabinoids, Δ9-Tetrahydrocannibinol, Cannabidiol and Cannabinol

  • M. A. Huestis
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 168)

Abstract

Increasing interest in the biology, chemistry, pharmacology, and toxicology of cannabinoids and in the development of cannabinoid medications necessitates an understanding of cannabinoid pharmacokinetics and disposition into biological fluids and tissues. A drug’s pharmacokinetics determines the onset, magnitude, and duration of its pharmacodynamic effects. This review of cannabinoid pharmacokinetics encompasses absorption following diverse routes of administration and from different drug formulations, distribution of analytes throughout the body, metabolism by different tissues and organs, elimination from the body in the feces, urine, sweat, oral fluid, and hair, and how these processes change over time. Cannabinoid pharmacokinetic research has been especially challenging due to low analyte concentrations, rapid and extensive metabolism, and physicochemical characteristics that hinder the separation of drugs of interest from biological matrices—and from each other—and lower drug recovery due to adsorption of compounds of interest to multiple surfaces. Δ 9-Tetrahydrocannabinol, the primary psychoactive component of Cannabis sativa, and its metabolites 11-hydroxy-Δ 9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol are the focus of this chapter, although cannabidiol and cannabinol, two other cannabinoids with an interesting array of activities, will also be reviewed. Additional material will be presented on the interpretation of cannabinoid concentrations in human biological tissues and fluids following controlled drug administration.

Keywords

Cannabinoids Pharmacokinetics Tetrahydrocannabinol Cannabidiol Absorption Distribution Metabolism Excretion Interpretation Oral fluid Sweat Hair Plasma Urine Alternate matrix Marijuana 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adams IB, Martin BR (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91:1585–1614PubMedCrossRefGoogle Scholar
  2. Agurell S, Leander K (1971) Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec 8:391–402PubMedGoogle Scholar
  3. Agurell S, Gillespie H, Halldin M, Hollister LE, Johansson E, Lindgren JE, Ohlsson A, Szirmai M, Widman M (1984) A review of recent studies on the pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol, cannabidiol and cannabinol in man. In: Paton SW, Nahas GG (eds) Marijuana’ 84. IRL Press, Oxford, pp 49–62Google Scholar
  4. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L (1986) Pharmacokinetics and metabolism of delta-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38:21–43PubMedGoogle Scholar
  5. Atkinson HC, Begg EJ, Darrlow BA (1988) Drugs in human milk clinical pharmacokinetic considerations. Clin Pharmacokinet 14:217–240PubMedGoogle Scholar
  6. Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM (1992) Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther 261:114–122PubMedGoogle Scholar
  7. Bailey JR, Cunny HC, Paule M, Slikker W Jr (1987) Fetal disposition of delta-9-tetrahydrocannbinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol 90:315–321PubMedCrossRefGoogle Scholar
  8. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84–87PubMedCrossRefGoogle Scholar
  9. Balabanova S, Schneider E (1989) Nachweis von drogen im schweis. Beitr Gerichtl Med 48:45–49Google Scholar
  10. Ben-Zvi Z, Burstein S (1974) 7-Oxo-delta-1-tetrahydrocannabinol: a novel metabolite of delta 1 tetrahydrocannabinol. Int J Clin Pharmacol Ther 8:223–229Google Scholar
  11. Ben-Zvi Z, Bergen JR, Burstein S, Sehgal PK, Varanelli C (1976)The metabolism of deltatetrahydrocannabinol in the rhesus monkey. In: Braude MC, Szara S (eds) The pharmacology of marijuana. Raven Press, New York, pp 63–75Google Scholar
  12. Benowitz NL, Nguyen TL, Jones RT, Herning RI, Bachman J (1980) Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 28:115–117PubMedCrossRefGoogle Scholar
  13. Binitie A (1975) Psychosis following ingestion of hemp in children. Psychopharmacologia 44:301–302PubMedCrossRefGoogle Scholar
  14. Blackard C, Tennes K (1984) Human placental transfer of cannabinoids. N Engl J Med 311:797PubMedGoogle Scholar
  15. Blanc JA, Manneh VA, Ernst R, Berger DE, de Keczer SA, Chase C, Centofanti JM, DeLizza AJ (1993) Adsorption losses from urine-bases cannabinoid calibrators during routine use. Clin Chem 39:1705–1717PubMedGoogle Scholar
  16. Bloom AS (1982) Effect of delta-9-tetrahydrocannabinol on the synthesis of dopamine and norepinephrine in mouse brain synaptosomes. J Pharmacol Exp Ther 221:97–103PubMedGoogle Scholar
  17. Bornheim LM, Lasker JM, Raucy JL (1992) Human hepatic microsomal metabolism of delta-1-tetrahydrocannabinol. Drug Metab Dispos 20:241–246PubMedGoogle Scholar
  18. Brenneisen R, Egli A, ElSohly MA, Henn V, Spiess Y (1996) The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 34:446–452PubMedGoogle Scholar
  19. Burstein S, Rosenfeld J, Wittstruck T (1972) Isolation and characterization of two major urinary metabolites of delta-1-tetrahydrocannabinol. Science 176:422–424PubMedGoogle Scholar
  20. Cairns ER, Howard RC, Hung CT, Menkes DB (1990) Saliva THC levels and cannabis intoxication. Report No. 2411, Chemistry Division, Division of Scientific and Industrial Research, Lower Hutt, New Zealand, pp 1–71Google Scholar
  21. Cairns T, Kippenberger DJ, Scholtz H, Baumgartner WA (1995) determination of carboxy-THC in hair by mass spectrometry/mass spectrometry. In: de Zeeuw RA, Al Hosani I, Al Munthiri S, Maqbool A (eds) Hair Analysis in Forensic Toxicology: proceedings of the 1995 international conference and workshop. The Organizing Committee of the conference, Abu Dhabi, pp 185–193Google Scholar
  22. Cami J, Guerra D, Ugena B, Segura J, de La Torre R (1991) Effect of subject expectancy on the THC intoxication and disposition from smoked hashish cigarettes. Pharmacol Biochem Behav 40:115–119PubMedGoogle Scholar
  23. Chiang CN, Rapaka RS (1987) Pharmacokinetics and disposition of cannabinoids. In: Rapaka RS, Makriyannis A (eds) NIDA research monograph—structure-activity relationships of the cannabinoids. National Institute on Drug Abuse, Rockville, pp 173–188Google Scholar
  24. Christophersen AS (1986) TetraHydroCannabinol stability in whole blood: plastic versus glass containers. J Anal Toxicol 10:129–131PubMedGoogle Scholar
  25. Cirimele V (1996) Cannabis and amphetamine determination in human hair. In: Kintz P (ed) Drug testing in hair. CRC Press, Boca Raton, pp 181–189Google Scholar
  26. Cirimele V, Sachs H, Kintz P, Mangin P (1996) Testing human hair for cannabis. III. Rapid screening procedure for the simultaneous identification of delta9-tetrahydrocannabinol, cannabinol, and cannabidiol. J Anal Toxicol 20:13–16PubMedGoogle Scholar
  27. Claussen U, Korte F (1968) Uber das verhalten von hanf und von delta-9-6a, 10a-trans-tetrahydrocannabinol biem rauchen. Justus Liebigs Ann Chem 713:162–165PubMedGoogle Scholar
  28. Cone EJ, Lange R, Darwin WD (1998) In vivo adulteration: excess fluid ingestion causes false-negative marijuana and cocaine urine test results. J Anal Toxicol 22:460–473PubMedGoogle Scholar
  29. Dewey WL, McMillan DE, Harris LS, Turk RF (1972) Distribution of radioactivity in brain of tolerant and nontolerant pigeons treated with 3-H-delta-9-tetrahydrocannabinol. Biochem Pharmacol 22:399–405Google Scholar
  30. Ehorn C, Fretthold D, Maharaj M (1994) Ion trap GC/MS/MS for analysis of THC from sweat. Abstract presented at the Society of Forensic Toxicologists annual meeting, Tampa, 31 October-4 November, p 11Google Scholar
  31. Ellis GM, Mann MA, Judson BA, Schramm NT, Tashchian A (1985) Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 38:572–578PubMedCrossRefGoogle Scholar
  32. ElSohly HN, Boeren EG, Turner CE, ElSohly MA (1984) Constituents of cannabis sativa L. XXIV: Cannabitetrol, a new polyhydroxylated cannabinoid. In: Agurell S, Dewey WL, Willette RE (eds) The cannabinoids: chemical, pharmacologic and therapeutic aspects. Academic Press, Orlando, pp 89–96Google Scholar
  33. Feng S, ElSohly MA, Salamone S, Salem MY (2000) Simultaneous analysis of delta-9-THC and its major metabolites in urine, plasma, and meconium by GC-MS using an immunoafffinity extraction procedure. J Anal Toxicol 24:395–402PubMedGoogle Scholar
  34. Foltz RL (1984) Analysis of cannabinoids in physiological specimens by gas chromatography/ mass spectrometry. In: Baselt RC (ed) Advances in analytical toxicology. Biomedical Publications, Foster City, pp 125–157Google Scholar
  35. Garrett ER, Hunt CA (1974) Physiochemical properties, solubility, and protein binding of delta-9-tetrahydrocannabinol. J Pharm Pharm Sci 63:1056–1064Google Scholar
  36. Garrett ER, Hunt CA (1977) Pharmacokinetics of delta-9-tetrahydrocannabinol in dogs. J Pharm Pharm Sci 66:395–406Google Scholar
  37. Gjerde H, Beylich KM, Morland J (1993) Incidence of alcohol and drugs in fatally injured car drivers in Norway. Accid Anal Prev 25:479–483PubMedCrossRefGoogle Scholar
  38. Green MD, Belanger G, Hum DW, Belanger A, Tephly TR (1997) Glucuronidation of opioids, carboxylic acid-containing drugs, and hydroxylated xenobiotics catalyzed by expressed monkey UDP-glucuronosyltransferase 2B9 protein. Drug Metab Dispos 25:1389–1394PubMedGoogle Scholar
  39. Greene ML, Saunders DR (1974) Metabolism of tetrahydrocannabinol by the small intestine. Gastroenterology 66:365–372PubMedGoogle Scholar
  40. Gross SJ, Soares JR (1978) Validated direct blood delta-9-THC radioimmune quantitation. J Anal Toxicol 2:98–100Google Scholar
  41. Gross SJ, Worthy TE, Nerder L, Zimmermann EG, Soares JR, Lomax P (1985) Detection of recent cannabis use by saliva delta-9-THC radioimmunoassay. J Anal Toxicol 9:1–5PubMedGoogle Scholar
  42. Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327–360PubMedGoogle Scholar
  43. Gustafson RA, Moolchan ET, Barnes A, Levine B, Huestis MA (2003) Validated method for the simultaneous determination of delta-9-tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatography-mass spectrometry with positive chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci 798:145–154PubMedGoogle Scholar
  44. Guy GW, Robson PJ (2004a) A phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis basedmedicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215). J Cannabis Ther 3:121–152Google Scholar
  45. Guy GW, Robson PJ (2004b) A phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis basedmedicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers (GWPK0112). J Cannabis Ther 3:79–120Google Scholar
  46. Hall BJ, Satterfield-Doerr M, Parikh AR, Brodbelt JS (1998) Determination of cannabinoids in water and human saliva by solid-phase microextraction and quadrupole ion trap gas chromatography-mass spectrometry. Anal Chem 70:1788–1796PubMedCrossRefGoogle Scholar
  47. Halldin MM, Widman M, Bahr CV, Lindgren JE, Martin BR (1982) Identification of in vitro metabolites of delta-tetrahydrocannabinol formed by human livers. Drug Metab Dispos 10:297–301PubMedGoogle Scholar
  48. Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (—) delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95:8268–8273PubMedCrossRefGoogle Scholar
  49. Hanson VW, Buonarati MH, Baselt RC, Wade NA, Yep C, Biasotti AA, Reeve VC, Wong AS, Orbanowsky MW (1983) Comparison of 3H-and 125I-radioimmunoassay and gas chromatography/ mass spectrometry for the determination of delta-9-tetrahydrocannabinol and cannabinoids in blood and serum. J Anal Toxicol 7:96–102PubMedGoogle Scholar
  50. Harder S, Rietbrock S (1997) Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther 35:155–159PubMedGoogle Scholar
  51. Harvey DJ (2001) Absorption, distribution, and biotransformation of the cannabinoids. In: Nahas GG, Sutin KM, Harvey DJ, Agurell S (eds) Marijuana and medicine. Humana Press, Totowa, pp 91–103Google Scholar
  52. Harvey DJ, Mechoulam R (1990) Metabolites of cannabidiol identified in human urine. Xenobiotica 20:303–320PubMedGoogle Scholar
  53. Harvey DJ, Paton WDM (1986) Metabolism of the cannabinoids. Rev Biochem Toxicol 6:221–264Google Scholar
  54. Harvey DJ, Martin BR, Paton WDM (1979) Identification and measurement of cannabinoids and their in vivo metabolites in liver by gas chromatography-mass spectrometry. In: Nahas GG, Paton WDM (eds) Marijuana: biological effects. Pergamon Press, Oxford, pp 45–62Google Scholar
  55. Hawks RL (1982) The constituents of cannabis and the disposition and metabolism of cannabinoids. In: Hawks R (ed) The analysis of cannabinoids in biological Fluids. Research Monograph 42. National Institute on Drug Abuse, Rockville, pp 125–137Google Scholar
  56. Hawks RL (1983) Developments in cannabinoid analyses of body fluids: implications for forensic applications. In: Agurell S, Dewey W, Willette R (eds) The cannabinoids: chemical, pharmacologic, and therapeutic aspects. Academic Press, Rockville, pp 1–12Google Scholar
  57. Heishman SJ, Stitzer ML, Yingling JE (1989) Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance. Pharmacol Biochem Behav 34:173–179PubMedCrossRefGoogle Scholar
  58. Holdcroft A (1984) Pain therapy. In: Grotenhermen F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative Healing Press, New York, pp 181–186Google Scholar
  59. Huang W, Moody DE, Andrenyak DM, Smith EK, Foltz RL, Huestis MA, Newton JF (2001) Simultaneous determination of delta-9-tetrahydrocannabinol and 11-nor-9-carboxydelta-9-tetrahydrocannabinol in human plasma by solid phase extraction and gas chromatography—negative ionchemical ionization—massspectrometry. J Anal Toxicol 25:531–537PubMedGoogle Scholar
  60. Huestis MA, Cone EJ (1998a) Alternative testing matrices. In: Karch SB (ed) Drug abuse handbook. CRC Press, Boca Raton, pp 799–857Google Scholar
  61. Huestis MA, Cone EJ (1998b) Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 22:445–454PubMedGoogle Scholar
  62. Huestis MA, Cone EJ (2004) Relationship of Delta-9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol 28:394–399PubMedGoogle Scholar
  63. Huestis MA, Dickerson S, Cone EJ (1992a) Can saliva THC levels be correlated to behavior? American Academy of Forensic Sciences Annual Meeting, New Orleans, p 190Google Scholar
  64. Huestis MA, Henningfield JE, Cone EJ (1992b) Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16:276–282PubMedGoogle Scholar
  65. Huestis MA, Henningfield JE, Cone EJ (1992c) Blood cannabinoids. II.Models for the prediction of time of marijuana exposure from plasma concentrations of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol 16:283–290PubMedGoogle Scholar
  66. Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ (1992d) Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther 52:31–41PubMedCrossRefGoogle Scholar
  67. Huestis MA, Mitchell JM, Cone EJ (1995) Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol 19:443–449PubMedGoogle Scholar
  68. Huestis MA, Mitchell JM, Cone EJ (1996) Urinary excretion profiles of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J Anal Toxicol 20:441–452PubMedGoogle Scholar
  69. Hunt CA, Jones RT (1980) Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 215:35–44PubMedGoogle Scholar
  70. Hunt CA, Jones RT, Herning RI, Bachman J (1981) Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet Biopharm 9:245–260PubMedCrossRefGoogle Scholar
  71. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF (1996) Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9:365–373PubMedCrossRefGoogle Scholar
  72. Jehanli A, Brannan S, Moore L, Spiehler VR (2001) Blind trials of an onsite saliva drug test for marijuana and opiates. J Forensic Sci 46:1214–1220PubMedGoogle Scholar
  73. Joern WA (1992) Surface adsorption of the urinary marijuana carboxy metabolite: the problem and a partial solution. J Anal Toxicol 16:401PubMedGoogle Scholar
  74. Johansson E, Halldin MM (1989) Urinary excretion half-life of delta1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J Anal Toxicol 13:218–223PubMedGoogle Scholar
  75. Johansson E, Agurell S, Hollister LE, Halldin MM (1988) Prolonged apparent half-life of delta-1-tetrahydrocannabinol in plasma of chronic marijuana users. J PharmPharmacol 40:374–375Google Scholar
  76. Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK (1989a) Terminal elimination plasma half-life of delta-1-tetrahydrocannabinol (selta-1-THC) in heavy users of marijuana. Eur J Clin Pharmacol 37:273–277PubMedGoogle Scholar
  77. Johansson E, Noren K, Sjovall J, Halldin MM (1989b) Determination of delta-1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 3:35–38PubMedCrossRefGoogle Scholar
  78. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003) Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. J Am Med Assoc 290:1757–1762CrossRefGoogle Scholar
  79. Kelly P, Jones RT (1992) Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 16:228–235PubMedGoogle Scholar
  80. Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, Abusada GA (1995a) Cannabinoids in humans. I. Analysis of delta-9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J Anal Toxicol 19:285–291PubMedGoogle Scholar
  81. Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, McWilliams ME, Nixon FE, Fitzgerald MJ, Reeves RR, Wood MJ (1995b) Cannabinoids in humans. II. The in.uence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol 19:292–298PubMedGoogle Scholar
  82. Kidwell DA, Holland JC, Athanaselis S (1998) Testing for drugs of abuse in saliva and sweat. J Chromatogr 713:111–135Google Scholar
  83. Kim KR, Yoon HR (1996) Rapid screening for acidic non-steroidal anti-inflammatory drugs in urine by gas chromatography-mass spectrometry in the selected-ion monitoring mode. J Chromatogr B Biomed Appl 682:55–66PubMedGoogle Scholar
  84. Kintz P, Cirimele V, Mangin P (1995) Testing human hair for cannabis II. Identifcation of THC-COOH by GC-MS-NCI as a unique proof. J Forensic Sci 40:619–622PubMedGoogle Scholar
  85. Kintz P, Brenniesen R, Bundeli P, Mangin P (1997) Sweat testing for heroin and metabolites in a heroin maintenance program. Clin Chem 43:736–739PubMedGoogle Scholar
  86. Kintz P, Cirimele V, Ludes B (2000) Detection of cannabis in oral fluid (saliva) and forehead wipes (sweat) from impaired drivers. J Anal Toxicol 24:557–561PubMedGoogle Scholar
  87. Kreuz DS, Axelrod J (1973) Delta-9-tetrahydrocannabinol: localization in body fat. Science 179:391–393PubMedGoogle Scholar
  88. Krishna DR, Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26:144–160PubMedCrossRefGoogle Scholar
  89. Law B, Mason PA, Moffat AC, Gleadle RI, King LJ (1984) Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol 36:289–294PubMedGoogle Scholar
  90. Lee CC, Chiang CN (1985) Appendix.Maternal-fetal transfer of abused substances: pharmacokinetic and pharmacodynamic data. In: Chiang CN, Lee CC (eds) NIDA Research monograph 60. U.S. Department of Health and Human Services, Rockville, pp 110–147Google Scholar
  91. Lemberger L, Silberstein SD, Axelrod J, Kopin IJ (1970) Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science 170:1320–1322PubMedGoogle Scholar
  92. Lemberger L, Tamarkin NR, Axelrod J (1971) Delta-9-tetrahydrocannabinol: metabolism and disposition in long-term marihuana smokers. Science 173:72–74PubMedGoogle Scholar
  93. Lemberger L, Crabtree RE, Rowe HM (1972) 11-hydroxy-delta-9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marijuana in man. Science 177:62–64PubMedGoogle Scholar
  94. Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H (1981) Clinical effects and plasma levels of delta-9-tetrahydrocannabinol (delta-9-THC) in heavy and light users of cannabis. Psychopharmacology (Berl) 74:208–212PubMedCrossRefGoogle Scholar
  95. Malfait AM, Galllily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic inmurine collagen-induced arthritis. Proc Natl Acad Sci U S A 97:9561–9566PubMedCrossRefGoogle Scholar
  96. Manno JE, Ferslew KE, Manno BR (1984) Urine excretion patterns of cannabinoids and the clinical application of the EMIT-d.a.u. cannabinoid urine assay for substance abuse treatment. In: Agurell S, Dewey WL, Willette RE (eds) The cannabinoids: chemical, pharmacologic, and therapeutic aspects. Harcourt Brace Jonanovich, Orlando, pp 281–290Google Scholar
  97. Manno JE, Manno BR, Kemp PM, Alford DD, Abukhalaf IK, McWilliams ME, Hagaman FN, Fitzgerald MJ (2001) Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta-9-tetrahydrocannabinol, 11-hydroxy-delta-9-tetrahydrocannabinol, and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol 25:538–549PubMedGoogle Scholar
  98. Martin BR, Dewey WL, Harris LS, Beckner JS (1977) 3H-Delta-9-tetrahydrocannbinol distribution in pregnant dogs and their fetuses. Res Commun Chem Pathol Pharmacol 17:457–470PubMedGoogle Scholar
  99. Mason AP, McBay AJ (1984) Ethanol, marijuana, and other drug use in 600 drivers killed in single-vehicle crashers in North Carolina, 1978–1981. J Forensic Sci 29:987–1026PubMedGoogle Scholar
  100. Mason AP, McBay AJ (1985) Cannabis: pharmacology and interpretation of effects. J Forensic Sci 30:615–631PubMedGoogle Scholar
  101. Matsunaga T, Iwawaki Y, Watanabe K, Yamamoto I, Kageyama T, Yoshimura H (1995) Metabolism of delta-9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci 56:2089–2095PubMedCrossRefGoogle Scholar
  102. Mattes RD, Shaw LM, Edling-Owens J, Engelman K, ElSohly MA (1993) Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav 44:745–747PubMedCrossRefGoogle Scholar
  103. Mattes RD, Engelman K, Shaw LM, ElSohly MA (1994) Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 49:187–195PubMedCrossRefGoogle Scholar
  104. McArdle K, Mackie P, Pertwee R, Guy G, Whittle B, Hawksworth G (2001) Selective inhibition of delta-9-tetrahydrocannabinol metabolite formation by cannabidiol in vitro (abstract) in Proceedings of the BTS Annual Congress. Toxicology 168:133–134Google Scholar
  105. McBurney LJ, Bobbie BA, Sepp LA (1986) GC/MS and Emit analyses for delta-9-tetrahydrocannabinol metabolites in plasma and urine of human subjects. J Anal Toxicol 10:56–64PubMedGoogle Scholar
  106. Mechoulam R (1970) Marihuana chemistry. Science 168:1159–1166PubMedGoogle Scholar
  107. Mechoulam R, Zvi ZB, Agurell S, Nilsson IM, Nilsson JLG, Edery H, Grunfeld Y (1973) Delta-6 tetrahydrocannabinol-7-oic acid, a urinary delta-6-THC metabolite: isolation and synthesis. Experientia 29:1193–1195PubMedCrossRefGoogle Scholar
  108. Meier HJ, Vonesch HJ (1997) Cannabis-intoxikationnach salatgenuss. Schweiz Med Wochenschr 127:214–218PubMedGoogle Scholar
  109. Melamede R (1984) Possible mechanisms in autoimmune diseases. In: Grotenhermen F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative Healing Press, New York, pp 111–122Google Scholar
  110. Moeller MR, Doerr G, Warth S (1992) Simultaneous quantitation of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in serumby GC/MS using deuterated internal standards and its application to a smoking study and forensic cases. J Forensic Sci 37:969–983PubMedGoogle Scholar
  111. Moore C, Guzaldo F, Donahue T (2001) The determination of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in hair using negative ion gas chromatographymass spectrometry and high-volume injection. J Anal Toxicol 25:555–558PubMedGoogle Scholar
  112. Mura P, Kintz P, Papet Y, Ruesch G, Piriou A (1999) Evaluation of six rapid tests for screening of cannabinoids in sweat, saliva and urine. Acta Clin Belg 1:35–38Google Scholar
  113. Nebro W, Barnes A, Gustafson R, Moolchan E, Huestis M (2004) Delta-9-tetrahydrocannabinol (THC), 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THCCOOH) in human plasma following oral administration of hemp oil. 2004 FBI/SOFT/TIAFT MeetingGoogle Scholar
  114. Niedbala RS, Kardos KW, Fritch DF, Kardos S, Fries T, Waga J (2001) Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol 25:289-303Google Scholar
  115. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409–416PubMedCrossRefGoogle Scholar
  116. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1981) Plasma levels of delta-9-tetrahydrocannabinol after intravenous, oral and smoke administration. NIDA Res Monogr 34:250–256PubMedGoogle Scholar
  117. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1982) Single dose kinetics of deuterium-labelled delta-1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Environ Mass Spectrom 9:6–10CrossRefGoogle Scholar
  118. Ohlsson A, Agurell S, Londgren JE, Gillespie HK, Hollister LE (1985) Pharmacokinetic studies of delta-1-tetrahydrocannabinol in man. In: Barnett G, Chiang CN (eds) Pharmacokinetics and pharmacodynamics of psychoactive drugs. Mosby Yearbook, St Louis, pp 75–92Google Scholar
  119. Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE (1986) Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 13:77–83PubMedCrossRefGoogle Scholar
  120. Owens SM, McBay AJ, Reisner HM, Perez-Reyes M (1981) 125 l radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with a solid-phase second-antibody separation method. Clin Chem 27:619–624PubMedGoogle Scholar
  121. Peat MA (1989) Distribution of delta-9-tetrahydrocannabinol and its metabolites. In: Baselt RC (ed) Advances in analytical toxicology II. Year Book Medical Publishers, Chicago, pp 186–217Google Scholar
  122. Peel HW, Perrigo BJ, Mikhael NZ (1984) Detection of drugs in saliva of impaired drivers. J Forensic Sci 29:185–189PubMedGoogle Scholar
  123. Perez-Reyes M (1985) Pharmacodynamics of certain drugs of abuse. In: Barnett G, Chiang CN (eds) Pharmacokinetics and pharmacodynamics of psychoactive drugs. Biomedical Publications, Foster City, pp 287–310Google Scholar
  124. Perez-Reyes M (1990) Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. In: Chiang CN, Hawks RL (eds) Research findings on smoking of abused substances. NIDA Research Monograph 99, Rockville, pp 42–62Google Scholar
  125. Perez-Reyes M, Wall ME (1982) Presence of delta-9-tetrahydrocannabinol in human milk. N Engl J Med 307:819–820PubMedGoogle Scholar
  126. Perez-Reyes M, Timmons MC, Lipton MA, Davis KH, Wall ME (1972) Intravenous injection in man of delta-9-tetrahydrocannabinol and 11-OH-delta-9-tetrahydrocannabinol. Science 177:633–635PubMedGoogle Scholar
  127. Perez-Reyes M, Lipton MA, Timmons MC, Wall ME, Brine DR, Davis KH (1973a) Pharmacology of orally administered delta-9-tetrahydrocannabinol. Clin Pharmacol Ther 14:48–55PubMedGoogle Scholar
  128. Perez-Reyes M, Timmons MC, Davis KH, Wall EM (1973b) A comparison of the pharmacological activity in man of intravenously administered delta-9-tetrahydrocannabinol, cannabinol and cannabidiol. Experientia 29:1368–1369PubMedCrossRefGoogle Scholar
  129. Perez-Reyes M, Owens SM, Di Guiseppi S (1981) The clinical pharmacology and dynamics of marijuana cigarette smoking. J Clin Pharmacol 21:201S–207SPubMedGoogle Scholar
  130. Perez-Reyes M, Di Guiseppi S, Davis KH, Schindler VH, Cook CE (1982) Comparison of effects of marijuana cigarettes of three different potencies. Clin Pharmacol Ther 31:617–624PubMedCrossRefGoogle Scholar
  131. Pertwee RG (2004) The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V (ed) Cannabinoids. Kluwer Academic/Plenum Publishers, New York, pp 32–83Google Scholar
  132. Plasse T (1984) Antiemetic effects of cannabinoids. In: Grotenhermen F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative Healing Press, New York, pp 165–180Google Scholar
  133. Samyn N, van Haeren C (2000) On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users. Int J Legal Med 113:150–154PubMedCrossRefGoogle Scholar
  134. Shaw LM, Edling-Owens J, Mattes R (1991) Ultrasensitive measurement of delta-9-tetrahydrocannabinol with a high energy dynode detector and electron-capture negative chemical-ionization mass spectrometry. Clin Chem 37:2062–2068PubMedGoogle Scholar
  135. Soares JR, Gross SJ (1976) Separate radioimmune measurements of body fluid delta-9THC and 11-nor-9-carboxy-delta-THC. Life Sci 19:1711–1717PubMedCrossRefGoogle Scholar
  136. Soares JR, Grant JD, Gross SJ (1982) Significant developments in radioimmune methods applied to delta-9-THC and its 9-substitutedmetabolites. In: Hawks R (ed) NIDA Research Monograph 42: National Institute on Drug Abuse, Bethesda, pp 44–55Google Scholar
  137. Sporkert F, Pragst F, Ploner CJ, Tschirch A, Stadelmann AM (2001) Pharmacokinetic investigations and delta-9-tetrahydrocannabinol and its metabolites after single administration of 10 mg Marinol in attendance of a psychiatric study. The Annual Meeting of The International Association of Forensic Toxicologists, Prague, pp 1–62Google Scholar
  138. Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR (2004) Human skin permeation of delta-8-tetrahydrocannabinol, cannabidiol and cannabinol. J Pharm Pharmacol 56:291–297PubMedCrossRefGoogle Scholar
  139. Turner CE, ElSohly MA, Boeren EG (1980) Constituents of cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 43:169–234PubMedCrossRefGoogle Scholar
  140. Vaughan CW, Christie MJ (1984) Mechanisms of cannabinoid analgesia. In: Grotenhermen F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative Healing Press, New York, pp 89–100Google Scholar
  141. Wall ME, Perez-Reyes M (1981) The metabolism of delta-9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 21:178S–189SPubMedGoogle Scholar
  142. Wall ME, Taylor HL (1984) Conjugation of acidic metabolites of delta-8 and delta-9-THC in man. In: Harvey DJ, Paton SW, Nahas GG (eds) Marihuana 84 Proceedings of the Oxford Symposium on Cannabis. IRL Press Limited, Oxford, pp 69–76Google Scholar
  143. Wall ME, Brine DR, Perez-Reyes M (1976) Metabolism of cannabinoids in man. In: Braude MC, Szara S (eds) The Pharmacology of marihuana. Raven Press, New York, pp 93–113Google Scholar
  144. Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M (1983) Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34:352–363PubMedCrossRefGoogle Scholar
  145. Watanabe K, Tanaka T, Yamamoto I, Yoshimura H (1988) Brain microsomal oxidation of delta-8-and delta-9-tetrahydrocannabinol. Biochem Biophys Res Commun 157:75–80PubMedCrossRefGoogle Scholar
  146. Widman M, Agurell S, Ehrnebo M, Jones G (1974) Binding of (+) and (-)-delta1-tetrahydrocannabinols and (-)-7-hydroxy-delta1-tetrahydrocannabinol to blood cells and plasma proteins in man. J Pharm Pharmacol 26:914–916PubMedGoogle Scholar
  147. Widman M, Nordqvist M, Dollery CT, Briant RH (1975) Metabolism of delta-1-tetrahydrocannabinol by the isolated perfused dog lung. Comparison with in vitro liver metabolism. J Pharm Pharmacol 27:842–848PubMedGoogle Scholar
  148. Williams PL, Moffat AC (1980) Identification in human urine of delta-9-tetrahydrocannabinol-11-oic glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 32:445–448PubMedGoogle Scholar
  149. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:1517–1526PubMedCrossRefGoogle Scholar
  150. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology (Berl) 76:245–250PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • M. A. Huestis
    • 1
  1. 1.Chemistry and Drug MetabolismIntramural Research ProgramBaltimoreUSA

Personalised recommendations